OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	93
Future options for long-acting HIV treatment and prevention	65
The sounds of silencing: dynamic epigenetic control of HIV latency	46
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	44
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	31
Harnessing natural killer cells to target HIV-1 persistence	28
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	27
Editorial introductions	26
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	25
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	25
Editorial introduction	25
New latency-promoting agents for a block-and-lock functional cure strategy	20
Editorial introduction	19
Loneliness and social isolation in people with HIV	19
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	19
Challenges towards an AIDS-free generation in Africa and Asia	19
Persistent elite controllers as the key model to identify permanent HIV remission	18
Editorial introduction	18
Immunological effector mechanisms in HIV-1 elite controllers	17
Defining multimorbidity in people with HIV – what matters most?	17
The origins of new SARS-COV-2 variants in immuncompromised individuals	17
Role of follicular homing natural killer cells in HIV infection	16
Viral and immune predictors of HIV posttreatment control	16
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	16
Editorial introduction	15

Impact of coronavirus disease 2019 on co-morbidities in HIV	15
Renal adverse drug reactions	15
The multifaceted nature of HIV tissue reservoirs	14
New vector and vaccine platforms: mRNA, DNA, viral vectors	13
Mpox and the impact on people with HIV	13
Obesity among women with HIV	12
Beyond criminalization: reconsidering HIV criminalization in an era of reform	12
Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV	12
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	11
Gender and sex considerations in HIV and bone health	11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	11
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
Host factors predisposing to kidney disease in people with HIV	10
Editorial: New drugs for HIV: quo vadis?	10
Strategies to target the central nervous system HIV reservoir	10
HIV and cardiovascular disease: the role of inflammation	10
The severity of COVID-19 across the spectrum of HIV	10
Assessing proviral competence: current approaches to evaluate HIV-1 persistence	10
HIV drug resistance in various body compartments	9
Editorial introduction	9
Persistent HIV-1 transcription during ART: time to reassess its significance?	8
Causes and outcomes of hepatic fibrosis in persons living with HIV	8
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	8
Editorial introductions	7
Innovative models of care supporting people aging with HIV	7
Editorial introduction	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
Editorial: Is it time to implement injectable antiretroviral treatments globally?	6
The pathogenesis of obesity in people living with HIV	6
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
Editorial introductions	6
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	6
HIV-1 subtypes and latent reservoirs	6
Whole person HIV services: a social science approach	5
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	5
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	5
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	5
Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review	5
Towards a molecular profile of antiretroviral therapy-free HIV remission	5
Role of islatravir in HIV treatment and prevention: an update	5
Towards an HIV cure: one cell at a time	5
The innovative use of qualitative and mixed methods research to advance improvements along the HIV prevention and care continua	5
Editorial introductions	5
Scaling up preexposure prophylaxis to maximize HIV prevention impact	5
Human papillomavirus infection among adolescents living with HIV: a focus on prevention	4
The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence	4
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	4
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults	4
Editorial introductions	4

Cardiovascular disease risk in women living with HIV	4
Editorial introductions	4
Care of people aging with HIV in resource limited settings	4
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	4
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	4
Humanized mice for studying HIV latency and potentially its eradication	4
Editorial introduction	3
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	3
Editorial introductions	3
Monocytes across life span in HIV infection: lights and shadows	3
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	3
Post-intervention control in HIV immunotherapy trials	3
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	3
Delivery platforms for broadly neutralizing antibodies	3
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	3
Cognitive impairment in persons with HIV: changing aetiologies and management strategies	3
Editorial introduction	3
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	3
Pediatric immunotherapy and HIV control	3
Considerations for successful therapeutic immunization in HIV cure	3
Zika virus: an overview update	3
Management of pain and other palliative needs in older people with HIV	2
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	2
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	2
Hepatotoxicity of contemporary antiretroviral drugs	2
Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention	2
HIV T-cell immunogen design and delivery	2
Implementation of long-acting antiretroviral therapy in low-income and middle-income countries	2
The future of long-acting agents for preexposure prophylaxis	2
“Go”, “No Go,” or “Where to Go”; does microbiota dictate T cell exhaustion, programming, and HIV persistence?	2
Utilizing immunotherapy towards achieving a functional cure for HIV-1	2
The vaginal microbiome and HIV transmission dynamics	2
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection	2
HIV and obesity: updates in management strategies	2
Editorial introductions	2
Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic	2
Pulmonary comorbidities in people with HIV− the microbiome connection	2
Long-acting preexposure prophylaxis in low- and middle-income countries: key considerations for implementation	1
Cardiovascular health in people with perinatally acquired HIV – where do we stand?	1
Barriers and facilitators related to COVID-19 vaccine acceptance and uptake among people living with HIV	1
Editorial introductions	1
HIV cure: an acceptability scientific agenda	1
Targeting enhanced neutralizing antibody responses via increased germinal center activity: early-phase vaccine trials with novel clinical designs	1
Neuropathogenesis of acute HIV: mechanisms, biomarkers, and therapeutic approaches	1
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	1
Long-acting antiretroviral therapy in the context of viral suppression	1
Emerging role of natural killer cells in non-AIDS comorbidities during suppressive antiretroviral therapy	1
Humoral immunity in HIV-1 post-treatment controllers	1
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy	1
Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings	1
Elite controllers microbiome: unraveling the mystery of association and causation	1
Technologies for HIV-1 drug resistance testing: inventory and needs	1
Long-acting preexposure prophylaxis: early data on roll-out in the United States	1
Harnessing immune cells to eliminate HIV reservoirs	1
Pharmacological approaches to promote cell death of latent HIV reservoirs	1
Kidney disease in patients with HIV	1
Update on treatment as prevention of HIV illness, death, and transmission: sub-Saharan Africa HIV financing and progress towards the 95–95–95 target	1
Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV	1
Preventing perinatal HIV acquisition; current gaps and future perspectives	1
Promises and challenges: cabotegravir for preexposure prophylaxis	1
Stepping stones to cure in children with HIV	1
Editorial introductions	1
Lenacapavir: a first-in-class HIV-1 capsid inhibitor	1
A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117	1
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection	1
Advances in the mathematical modeling of posttreatment control of HIV-1	1
What's in a cure: designing a broad-spectrum HIV gene therapy	1